Top

27-09-2024 | NSCLC | Original Article

Treatment selection pattern and prognostic factors in older patients with non-small cell lung cancer at recurrence: an observational study

Authors: Dai Sonoda, Raito Maruyama, Yasuto Kondo, Masahito Naito, Masashi Mikubo, Kazu Shiomi, Yukitoshi Satoh

Abstract

Purpose

Society is aging, and the proportion of older patients with lung cancer is increasing. However, the treatment choices and prognoses for older patients with cancer recurrence remain unclear. We retrospectively investigated the treatment choices and prognoses of older patients with recurrence.

Methods

We conducted a retrospective review of 1100 patients who underwent complete resection for non-small cell lung cancer at Kitasato University Hospital between 2004 and 2017. Patients of ≥75 years of age were defined as older patients, and the prognosis and prognostic factors of these patients upon recurrence were examined.

Results

Among the 290 patients who developed recurrence, 106 experienced recurrence at an older age. The factors associated with survival after recurrence included sex, time to recurrence, number of recurrences, performance status at recurrence, and active treatment. As the age at recurrence increased, the proportion of patients who did not receive active treatment increased, as did the proportion for whom the reason was the patient’s and family’s preferences.

Conclusions

A considerable number of older patients who experience recurrence do not wish to receive active treatment. However, the prognosis can be improved by aggressive treatment for recurrence.

Kontis V, Bennett JE, Mathers CD, Li G, Foreman K, Ezzati M. Future life expectancy in 35 industrialised countries: projections with a Bayesian model ensemble. Lancet. 2017;389:1323–35. https://doi.org/10.1016/S0140-6736(16)32381-9.CrossRefPubMedPubMedCentral

Statistics Bureau of Japan. Summary of Population Estimates Results. Available from https://www.stat.go.jp/data/jinsui/2.html

Wang J, Wang Z, Niu B. Empirical analysis of preferences of older adults for care facilities in Japan: focusing on household structure and economic status. Healthcare (Basel). 2023;11:1843. https://doi.org/10.3390/healthcare11131843.CrossRefPubMed

Committee for Scientific Affairs, The Japanese Association for Thoracic Surgery, Shimizu H, Okada M, Tangoku A, Doki Y, Endo S, Fukuda H, et al. Thoracic and cardiovascular surgeries in Japan during 2017: annual report by the Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg. 2020;68:414–49. https://doi.org/10.1007/s11748-020-01298-2.CrossRef

Port JL, Mirza FM, Lee PC, Paul S, Stiles BM, Altorki NK. Lobectomy in octogenarians with non-small cell lung cancer: ramifications of increasing life expectancy and the benefits of minimally invasive surgery. Ann Thorac Surg. 2011;92:1951–7. https://doi.org/10.1016/j.athoracsur.2011.06.082.CrossRefPubMed

Brokx HA, Visser O, Postmus PE, Paul MA. Surgical treatment for octogenarians with lung cancer: results from a population-based series of 124 patients. J Thorac Oncol. 2007;2:1013–7. https://doi.org/10.1097/JTO.0b013e3181559fdf.CrossRefPubMed

Ogino H, Hanibuchi M, Sakaguchi S, Toyoda Y, Tezuka T, Kawano H, et al. The clinical features of older patients with lung cancer in comparison with their younger counterparts. Respir Investig. 2019;57:40–8. https://doi.org/10.1016/j.resinv.2018.10.003.CrossRefPubMed

Gridelli C, Perrone F, Gallo C, Cigolari S, Rossi A, Piantedosi F, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst. 2003;95:362–72. https://doi.org/10.1093/jnci/95.5.362.CrossRefPubMed

Kudoh S, Takeda K, Nakagawa K, Takada M, Katakami N, Matsui K, et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol. 2006;24:3657–63. https://doi.org/10.1200/JCO.2006.06.1044.CrossRefPubMed

10.

Okamoto I, Nokihara H, Nomura S, Niho S, Sugawara S, Horinouchi H, et al. Comparison of carboplatin plus pemetrexed followed by maintenance pemetrexed with docetaxel monotherapy in elderly patients with advanced nonsquamous non-small cell lung cancer: a phase 3 randomized clinical trial. JAMA Oncol. 2020;6: e196828. https://doi.org/10.1001/jamaoncol.2019.6828.CrossRefPubMedPubMedCentral

11.

Maemondo M, Minegishi Y, Inoue A, Kobayashi K, Harada M, Okinaga S, et al. First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study. J Thorac Oncol. 2012;7:1417–22. https://doi.org/10.1097/JTO.0b013e318260de8b.CrossRefPubMed

12.

Goto K, Nishio M, Yamamoto N, Chikamori K, Hida T, Maemondo M, et al. A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC). Lung Cancer. 2013;82:109–14. https://doi.org/10.1016/j.lungcan.2013.07.003.CrossRefPubMed

13.

Yamaguchi O, Imai H, Minemura H, Suzuki K, Wasamoto S, Umeda Y, et al. Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer. Cancer Chemother Pharmacol. 2020;85:761–71. https://doi.org/10.1007/s00280-020-04055-7.CrossRefPubMed

14.

Vaz Fragoso CA, Enright PL, McAvay G, Van Ness PH, Gill TM. Frailty and respiratory impairment in older persons. Am J Med. 2012;125:79–86. https://doi.org/10.1016/j.amjmed.2011.06.024.CrossRefPubMedPubMedCentral

15.

Newman AB, Gottdiener JS, Mcburnie MA, Hirsch CH, Kop WJ, Tracy R, et al. Associations of subclinical cardiovascular disease with frailty. J Gerontol A Biol Sci Med Sci. 2001;56:M158–66. https://doi.org/10.1093/gerona/56.3.m158.CrossRefPubMed

16.

Widdop RE, Vinh A, Henrion D, Jones ES. Vascular angiotensin AT2 receptors in hypertension and ageing. Clin Exp Pharmacol Physiol. 2008;35:386–90. https://doi.org/10.1111/j.1440-1681.2008.04883.x.CrossRefPubMed

17.

Iso-Markku P, Aaltonen S, Kujala UM, Halme HL, Phipps D, Knittle K, et al. Physical activity and cognitive decline among older adults: a systematic review and meta-analysis. JAMA Netw Open. 2024;7: e2354285. https://doi.org/10.1001/jamanetworkopen.2023.54285.CrossRefPubMedPubMedCentral

18.

Owonikoko TK, Ragin CC, Belani CP, Oton AB, Gooding WE, Taioli E, et al. Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. J Clin Oncol. 2007;25:5570–7. https://doi.org/10.1200/JCO.2007.12.5435.CrossRefPubMed

19.

Dalwadi SM, Szeja SS, Bernicker EH, Butler EB, Teh BS, Farach AM. Practice patterns and outcomes in elderly stage I non-small-cell lung cancer: a 2004 to 2012 SEER analysis. Clin Lung Cancer. 2018;19:e269–76. https://doi.org/10.1016/j.cllc.2017.11.004.CrossRefPubMed

20.

The Japan Lung Cancer Society. Definition of older. Available from https://www.haigan.gr.jp/guideline/2023/1/2/230102070100.html

21.

Postmus PE, Brambilla E, Chansky K, Crowley J, Goldstraw P, Patz EF Jr, et al. The IASLC Lung Cancer Staging Project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer. J Thorac Oncol. 2007;2:686–93. https://doi.org/10.1097/JTO.0b013e31811f4703.CrossRefPubMed

22.

Martini N, Melamed MR. Multiple primary lung cancers. J Thorac Cardiovasc Surg. 1975;70:606–12.CrossRefPubMed

23.

Miyata R, Hamaji M, Kawaguchi A, Shimazu Y, Ikeda M, Ishikawa M, et al. Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment for postoperative recurrent EGFR-mutated lung adenocarcinoma: a multi-institutional retrospective study. Eur J Cardiothorac Surg. 2022;62:ezac430. https://doi.org/10.1093/ejcts/ezac430.CrossRefPubMed

24.

Imai H, Kijima T, Azuma K, Kishi K, Saito H, Yamaguchi T, et al. First-line nivolumab plus ipilimumab with or without chemotherapy for Japanese patients with non-small cell lung cancer: LIGHT-NING study. Jpn J Clin Oncol. 2024;54:452–62. https://doi.org/10.1093/jjco/hyad195.CrossRefPubMedPubMedCentral

25.

Mun M, Nakao M, Matsuura Y, Ichinose J, Nakagawa K, Okumura S. Video-assisted thoracoscopic surgery lobectomy for non-small cell lung cancer. GenThorac Cardiovasc Surg. 2018;66:626–31. https://doi.org/10.1007/s11748-018-0979-x.CrossRef

26.

Zhiqiang W, Shaohua M. Perioperative outcomes of robotic-assisted versus video-assisted thoracoscopic lobectomy: a propensity score matched analysis. Thorac Cancer. 2023;14:1921–31. https://doi.org/10.1111/1759-7714.14938.CrossRefPubMedPubMedCentral

27.

Niibe Y, Nishimura T, Inoue T, Karasawa K, Shioyama Y, Jingu K, et al. Oligo-recurrence predicts favorable prognosis of brain-only oligometastases in patients with non-small cell lung cancer treated with stereotactic radiosurgery or stereotactic radiotherapy: a multi-institutional study of 61 subjects. BMC Cancer. 2016;16:659. https://doi.org/10.1186/s12885-016-2680-8.CrossRefPubMedPubMedCentral

28.

Tachibana T, Matsuura Y, Ninomiya H, Ichinose J, Nakao M, Okumura S, et al. Optimal treatment strategy for oligo-recurrence lung cancer patients with driver mutations. Cancers (Basel). 2024;16:464. https://doi.org/10.3390/cancers16020464.CrossRefPubMed

29.

Sonoda D, Kondo Y, Maruyama R, Naito M, Mikubo M, Shiomi K, et al. Prognosis of patients with recurrent nonsmall cell lung cancer who received the best supportive care alone. Curr Probl Surg. 2024;61: 101429. https://doi.org/10.1016/j.cpsurg.2023.101429.CrossRefPubMed

Title: Treatment selection pattern and prognostic factors in older patients with non-small cell lung cancer at recurrence: an observational study
Authors: Dai Sonoda
Raito Maruyama
Yasuto Kondo
Masahito Naito
Masashi Mikubo
Kazu Shiomi
Yukitoshi Satoh
Publication date: 27-09-2024
Publisher: Springer Nature Singapore
Keywords: NSCLC
NSCLC
Lung Cancer
Lung Cancer
Lung Cancer
Published in: Surgery Today
Print ISSN: 0941-1291
Electronic ISSN: 1436-2813
DOI: https://doi.org/10.1007/s00595-024-02938-3

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Webinar | 06-02-2024 | 20:00 (CET)

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Keynote webinar | Spotlight on modern management of frailty

Springer Medicine

Treatment selection pattern and prognostic factors in older patients with non-small cell lung cancer at recurrence: an observational study

Abstract

Purpose

Methods

Results

Conclusions

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Keynote webinar | Spotlight on modern management of frailty

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions